Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | CTSG | P08311 | 1/20 | 0.50 |
| ▸ | CTRC | Q99895 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19543253 | 0.85 | F2 (0.42) | F2ELANECTSGCTRCALDH1A1 | |
| SCHEMBL6857906 | 0.81 | F2 (0.62) | F2ELANECTSGCTRCALDH1A1 | |
| SCHEMBL14137983 | 0.78 | MAPT (0.34) | F2ELANECTSGCTRCALDH1A1 | |
| SCHEMBL3692053 | 0.76 | F2 (0.43) | F2ELANECTSGCTRCALDH1A1 | |
| SCHEMBL19239504 | 0.74 | CYP1B1 (0.45) | F2ELANECTSGCTRCALDH1A1 | |
| SCHEMBL14011308 | 0.73 | F2 (0.53) | F2ELANECTSGCTRCALDH1A1 | |
| SCHEMBL17146904 | 0.72 | CYP1B1 (0.60) | F2ELANECTSGCTRCALDH1A1 | |
| SCHEMBL15501088 | 0.72 | CYP1B1 (0.40) | F2ELANECTSGCTRCALDH1A1 | |
| SCHEMBL15730466 | 0.71 | PTGS1 (0.55) | ALDH1A1MGLLCNR1 | |
| SCHEMBL844833 | 0.71 | BLM (0.54) | F2ELANECTSGCTRCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3915556-A1 | RECTAL APPLICATION OF THALIDOMIDE IN PATIENTS WITH HEMORRHAGIC CHRONIC RADIATION PROCTITIS | Vonnahme, Franz Josef (DE) | 2021-12-01 | — | — | EP | disclosed |
| US-20190209704-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | SENSEI BIOTHERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-8143283-B1 | Methods for treating blood-born tumors with thalidomide | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8039488-B2 | Methods and compositions for inhibition of angiogenesis | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-7723361-B2 | Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide | CELGENE CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090036412-A1 | Methods and Compositions for Inhibition of Angiogenesis | D AMATO ROBERT J | 2009-02-05 | — | — | US | disclosed |
| US-RE40360-E1 | Methods for inhibition of angiogenesis with a composition comprising 3-hydroxythalidomide | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036412-A1 | Methods and Compositions for Inhibition of Angiogenesis | PGF, PTGS1, PTGIS | F2 3093/4885ELANE 597/4885CTSG 575/4885 |
| US-20190209704-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | CYTH3, CD47, FCGRT | F2 4272/4885ELANE 2733/4885CTSG 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.